Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma

Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma

Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer worldwide, and the overall survival of patients with unresectable disease is poor. In the last five years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment scenario of several hematological and so...

Full description

Bibliographic Details
Main Authors:	Alessandro Rizzo, Giovanni Brandi
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	Cancer Treatment and Research Communications
Subjects:	Hepatocellular carcinoma HCC Immune checkpoint inhibitors PD-L1 TMB
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468294221000277

Similar Items

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
by: Ran Qin, et al.
Published: (2023-12-01)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
by: Alessandro Rizzo, et al.
Published: (2021-02-01)

Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
by: Landon L. Chan, et al.
Published: (2022-03-01)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
by: Pei-Chang Lee, et al.
Published: (2020-01-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021-09-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
by: Bufu Tang, et al.
Published: (2020-10-01)

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
by: Chi-Leung Chiang, et al.
Published: (2019-11-01)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
by: Kimberly M. Burcher, et al.
Published: (2021-11-01)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Anne Dyhl-Polk, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020-12-01)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
by: Jin-Kai Feng, et al.
Published: (2022-11-01)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
by: Nicola Personeni, et al.
Published: (2021-11-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
by: Krista Y. Chen, et al.
Published: (2022-10-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
by: Li J, et al.
Published: (2023-04-01)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
by: Jun Ho Ji, et al.
Published: (2023-04-01)

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01)

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Lu Li, et al.
Published: (2022-06-01)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
by: Pei-Yi Chu, et al.
Published: (2021-10-01)

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
by: Hong-Fei Zhu, et al.
Published: (2023-06-01)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
by: Ze Zhang, et al.
Published: (2023-02-01)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)

Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
by: Xindan Kang, et al.
Published: (2023-08-01)

Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
by: Yi Zhang, et al.
Published: (2023-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Nikolaos Machairas, et al.
Published: (2022-04-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Samantha M. Ruff, et al.
Published: (2023-06-01)

Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child–Pugh Class A Advanced Hepatocellular Carcinoma
by: Kanan Alshammari, et al.
Published: (2023-12-01)

Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape
by: Tsung-Hao Liu, et al.
Published: (2022-08-01)

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
by: Christian Ihling, et al.
Published: (2019-02-01)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
by: Ye Wang, et al.
Published: (2021-06-01)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-08-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
by: Fucun Xie, et al.
Published: (2022-12-01)

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
by: Shengwei Tao, et al.
Published: (2023-01-01)

Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation
by: Nitin N. Katariya, et al.
Published: (2022-04-01)